New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 22, 2014
08:15 EDTGHDXGenomic Health announces two important international milestones
Genomic Health announced two important international milestones including additional reimbursement in Canada and the inclusion of the Oncotype DX breast cancer test in major German clinical guidelines. In Canada, the BC Cancer Agency in British Columbia agreed to fund the Oncotype DX breast cancer test for eligible patients, expanding reimbursement to more than 80% of the country's population. In Germany, updated guidelines from the AGO, or Gynecologic Oncology Working Group, now recommend the Oncotype DX breast cancer test as the only gene expression test to predict chemotherapy benefit in early-stage hormone receptor-positive invasive breast cancer.
News For GHDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
08:05 EDTGHDXGenomic Health reports publication of results from second Oncotype DX validation
Genomic Health announced multiple upcoming presentations at the 2014 Society of Urologic Oncology Annual Meeting, including the second large, independent clinical validation study of the Oncotype DX prostate cancer test and results from the first prostate cancer decision impact study. The results from the latest validation study of the test, conducted in collaboration with the Center for Prostate Disease Research, have been accepted for publication in European Urology. Separately, the results of the first decision impact study of the Oncotype DX prostate cancer test, conducted in collaboration with academic and community practices at Columbia University, Delaware Valley Urology and Orange County Urology, have been accepted for publication in Urology Practice, an official journal of the American Urological Association. Additionally, Genomic Health will present results from its first liquid biopsy study assessing multiple technologies, including next-generation sequencing, for their ability to detect and analyze the presence of bladder cancer in urine.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use